AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17672261 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐etch adhesive system (Xeno III)
Number of subjects: 67
Study 17672261 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate of direct pulp capping
Number of subjects: 67
Study 16248452 — intervention group
Group type: EXPERIMENTAL
Intervention: Four skinfold protocols
Number of subjects: 121
Study 16248452 — intervention group
Group type: EXPERIMENTAL
Intervention: Three girth measurement protocols
Number of subjects: 121
Study 16248452 — intervention group
Group type: EXPERIMENTAL
Intervention: Two bioelectric impedance analysis (BIA) instruments
Number of subjects: 121
Study 16248452 — intervention group
Group type: EXPERIMENTAL
Intervention: One near-infrared instrument
Number of subjects: 121
Study 16248452 — intervention group
Group type: COMPARATOR
Intervention: General comparison to underwater weighing (UWW)
Number of subjects: 121
Study 11916282 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (30 mg initial dose for at least 2 months, stopped 6 days before treatment)
Number of subjects: 42
Study 11916282 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker (atenolol 50-100 mg/d)
Number of subjects: 42
Study 10023503 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 14
Study 10023503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 14
Study 10023503 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 14
Study 8522632 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 200 mg and 300 mg once daily for 14 weeks
Number of subjects: 92
Study 8522632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 2401129 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem sustained-release formulation
Number of subjects: 49
Study 2401129 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 49
Study 447112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowachol (2 capsules, three times a day for 48 hours)
Number of subjects: 0
Study 447112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowachol (1 capsule, three times a day for 48 hours)
Number of subjects: 0
Study 447112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowachol (4 capsules, four times a day for 48 hours)
Number of subjects: 0
Study 31553377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lian gong group (n = 11)
Number of subjects: 36
Study 31553377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation group (n = 11)
Number of subjects: 36
Study 31553377 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 36
Study 28232346 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS Health Check intervention
Number of subjects: 0
Study 25967575 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 34
Study 25967575 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 34
Study 24256450 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + placebo diclofenac
Number of subjects: 547
Study 24256450 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac + placebo paracetamol
Number of subjects: 547
Study 24256450 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + diclofenac
Number of subjects: 547
Study 21323785 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hydrogen peroxide with composite resin
Number of subjects: 140
Study 21323785 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite with composite resin
Number of subjects: 140
Study 21323785 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5% hydrogen peroxide and sodium hypochlorite with composite resin
Number of subjects: 140
Study 21323785 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% EDTA with composite resin
Number of subjects: 140
Study 21323785 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lactic acid with composite resin
Number of subjects: 140
Study 21323785 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lactic acid with composite resin
Number of subjects: 140
Study 21323785 — intervention group
Group type: COMPARATOR
Intervention: No irrigant (control) with composite resin
Number of subjects: 140
Study 19674165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride once daily for 52 weeks
Number of subjects: 378
Study 19674165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 16930852 — intervention group
Group type: EXPERIMENTAL
Intervention: D,L‐fenfluramine (FEN) 60 mg oral after a 7‐day cocaine‐free period
Number of subjects: 8
Study 16930852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (96 mg intranasal)
Number of subjects: 8
Study 16930852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 mg cocaine)
Number of subjects: 8
Study 16930852 — intervention group
Group type: EXPERIMENTAL
Intervention: Second FEN challenge
Number of subjects: 8
Study 15577414 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine gel
Number of subjects: 64
Study 15577414 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (vehicle)
Number of subjects: 64
Study 15577414 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine gel with neurotoxin exposure
Number of subjects: 64
Study 15577414 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine gel without neurotoxin exposure
Number of subjects: 64
Study 11369252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based front-line intraperitoneal therapy
Number of subjects: 0
Study 11369252 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (not specified)
Number of subjects: 0
Study 9534319 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin 12,500 IU twice daily for 3 months
Number of subjects: 204
Study 9534319 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin treatment
Number of subjects: 204
Study 9534319 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study 8214753 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.005, 0.01, 0.02, or 0.05 mg/kg)
Number of subjects: 64
Study 8214753 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (0.1, 0.2, 0.4, or 1 mg/kg)
Number of subjects: 64
Study 8214753 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 64
Study 8214753 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 64
Study 3122278 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 mcg daily (given as two or four divided doses)
Number of subjects: 2900
Study 3122278 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 2900
Study 3122278 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (conventional doses)
Number of subjects: 2900
Study 31273763 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS-ICU
Number of subjects: 3282
Study 31273763 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS II
Number of subjects: 3282
Study 31273763 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 3282
Study 27318406 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless Group (porcine Freestyle® Medtronic bioprosthesis)
Number of subjects: 62
Study 27318406 — intervention group
Group type: COMPARATOR
Intervention: Stented Group (porcine Mosaïc® Medtronic bioprosthesis)
Number of subjects: 62
Study 26001508 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐EAM system
Number of subjects: 80
Study 26001508 — intervention group
Group type: COMPARATOR
Intervention: Conventional EAM system
Number of subjects: 80
Study 23136002 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ng desmopressin
Number of subjects: 72
Study 23136002 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 ng desmopressin
Number of subjects: 72
Study 23136002 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 ng desmopressin
Number of subjects: 72
Study 23136002 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ng desmopressin
Number of subjects: 72
Study 23136002 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ng desmopressin
Number of subjects: 72
Study 23136002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20214847 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-psychotic medications
Number of subjects: 418
Study 20214847 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior outpatient mental health use
Number of subjects: 418
Study 20214847 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic white race
Number of subjects: 418
Study 20214847 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ADCS-ADL scores
Number of subjects: 418
Study 20214847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower utility scores on HUI-III
Number of subjects: 418
Study 20214847 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse cognition on Mini-mental State Examination
Number of subjects: 418
Study 20214847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower scores on ADCS-ADL
Number of subjects: 418
Study 19501212 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/CMA (ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg)
Number of subjects: 377
Study 19501212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 16877180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI)
Number of subjects: 231
Study 16877180 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 231
Study 12668792 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (15 micro g/kg over 20 minutes)
Number of subjects: 44
Study 12668792 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (5 mg/kg over 20 minutes)
Number of subjects: 44
Study 12668792 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 44
Study 12668792 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 44
Study 10872310 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating routine before exercise
Number of subjects: 30
Study 10872310 — intervention group
Group type: COMPARATOR
Intervention: Control method (not specified)
Number of subjects: 30
Study 8826495 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables (education level, marital status)
Number of subjects: 254
Study 8826495 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and gender interaction
Number of subjects: 254
Study 8826495 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of pain
Number of subjects: 254
Study 8826495 — intervention group
Group type: EXPERIMENTAL
Intervention: Work status and litigation status interaction
Number of subjects: 254
Study 8826495 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive analysis of work status, education level, and marital status
Number of subjects: 254
Study 1592345 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (n = 15)
Number of subjects: 30
Study 1592345 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (n = 15)
Number of subjects: 30
Study 1592345 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol added to Epinephrine (n = 10)
Number of subjects: 30
Study 1592345 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol added to Norepinephrine (n = 10)
Number of subjects: 30
Study 6146875 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet on breast self-examination
Number of subjects: 28788
Study 6146875 — intervention group
Group type: COMPARATOR
Intervention: Control group (no booklet)
Number of subjects: 28788
Study 30649227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 200 mg BID
Number of subjects: 47
Study 30649227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30382903 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser hair depilation of the sacrococcygeal region
Number of subjects: 272
Study 30382903 — intervention group
Group type: COMPARATOR
Intervention: Best recommended standard of care
Number of subjects: 272
Study 25979609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (AVP) 20 IU
Number of subjects: 153
Study 25979609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 24 IU
Number of subjects: 153
Study 25979609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 22902348 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg orally once daily starting on cycle day 8 until follicle rupture or onset of next menses)
Number of subjects: 20
Study 22902348 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg orally once daily starting with LH surge for 6 days)
Number of subjects: 20
Study 22902348 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no treatment)
Number of subjects: 20
Study 21200344 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking slower uphill at 0.75 m·s on a 6° incline
Number of subjects: 12
Study 21200344 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking slower uphill
Number of subjects: 12
Study 21200344 — intervention group
Group type: COMPARATOR
Intervention: Brisk level walking
Number of subjects: 12
Study 19281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg tablet (test formulation)
Number of subjects: 64
Study 19281728 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg tablet (reference formulation)
Number of subjects: 64
Study 17309456 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 2% cream
Number of subjects: 60
Study 17309456 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel
Number of subjects: 60
Study 15679233 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristinamycin 1 g bid for 4 days
Number of subjects: 485
Study 15679233 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil 250 mg bid for 5 days
Number of subjects: 485
Study 11329468 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized assay using rabbit complement
Number of subjects: 0
Study 11329468 — intervention group
Group type: COMPARATOR
Intervention: Goldschneider assay using human complement
Number of subjects: 0
Study 8203786 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg
Number of subjects: 183
Study 8203786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 183
Study 3109088 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) starting one week prior to transplant
Number of subjects: 137
Study 3109088 — intervention group
Group type: COMPARATOR
Intervention: Hydration with a 5% dextrose solution containing electrolytes, minerals, trace elements, and vitamins (Control)
Number of subjects: 137
Study 3109088 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 137
Study 28891743 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 12 weeks of cardiorespiratory and strength exercises
Number of subjects: 28
Study 28891743 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - Treatment as usual
Number of subjects: 28
Study 28177705 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint essential oil (PEP)
Number of subjects: 7
Study 28177705 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study 26665571 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 µg i.v.
Number of subjects: 130
Study 26665571 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 10 units i.v.
Number of subjects: 130
Study 24160333 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) plus intercourse for six cycles
Number of subjects: 800
Study 24160333 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins plus intercourse for six cycles
Number of subjects: 800
Study 24160333 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) plus IUI for six cycles
Number of subjects: 800
Study 24160333 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropins plus IUI for six cycles
Number of subjects: 800
Study 24160333 — intervention group
Group type: COMPARATOR
Intervention: Control group (CC only)
Number of subjects: 800
Study 24160333 — intervention group
Group type: COMPARATOR
Intervention: Control group (gonadotropins only)
Number of subjects: 800
Study 21167339 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medical services use among women increased from 55% in Cohort 1 to 66% in Cohort 2 (P = .02)
Number of subjects: 1638
Study 21167339 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time from symptom onset to first medical contact: 84 minutes (men) vs 121 minutes (women) in Cohort 1; 59 minutes (men) vs 81 minutes (women) in Cohort 2 (P < .01)
Number of subjects: 1638
Study 21167339 — intervention group
Group type: EXPERIMENTAL
Intervention: Median door-to-balloon time was significantly longer among women compared with men in Cohort 2.
Number of subjects: 1638
Study 21167339 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex associated with a 34% (or 27-minute) increase in time from symptom onset to first medical contact.
Number of subjects: 1638
Study 21167339 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex associated with a 23% (or 13-minute) increase in time from hospital arrival to reperfusion therapy.
Number of subjects: 1638
Study 18424239 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaque screening
Number of subjects: 530
Study 18424239 — intervention group
Group type: COMPARATOR
Intervention: No plaque screening (control)
Number of subjects: 530
Study 17164991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 98
Study 17164991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12893503 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (16 sessions of Short Psychodynamic Supportive Psychotherapy) and pharmacotherapy (fluoxetine, amitriptyline, and moclobemide)
Number of subjects: 0
Study 12893503 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 0
Study 10886311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose methylprednisolone treatment for 15 days
Number of subjects: 50
Study 9323143 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 100
Study 9323143 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 100
Study 9323143 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck dissection
Number of subjects: 100
Study 8312196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cytoreduction after 3 cycles of chemotherapy
Number of subjects: 278
Study 8312196 — intervention group
Group type: COMPARATOR
Intervention: 3 further cycles of chemotherapy
Number of subjects: 278
Study 3087701 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition solution supplemented with 44.6% branched-chain amino acids (BCAA)
Number of subjects: 0
Study 3087701 — intervention group
Group type: COMPARATOR
Intervention: Standard total parenteral nutrition (19.0% BCAA)
Number of subjects: 0
Study 3087701 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BCAA and control)
Number of subjects: 0
Study 29655496 — intervention group
Group type: EXPERIMENTAL
Intervention: PBO long-lasting insecticidal nets
Number of subjects: 15469
Study 29655496 — intervention group
Group type: COMPARATOR
Intervention: Standard long-lasting insecticidal nets
Number of subjects: 15469
Study 29655496 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying
Number of subjects: 15469
Study 29655496 — intervention group
Group type: COMPARATOR
Intervention: No indoor residual spraying
Number of subjects: 15469
Study 27977707 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine
Number of subjects: 1053
Study 27977707 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A
Number of subjects: 1053
Study 25234679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty (PCB)
Number of subjects: 50
Study 25234679 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 50
Study 24131880 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial profile subgroup with higher levels of psychosocial problems
Number of subjects: 92
Study 24131880 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup membership
Number of subjects: 92
Study 20573926 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 230
Study 20573926 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel (chemotherapy)
Number of subjects: 230
Study 19088832 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blockers
Number of subjects: 831
Study 15766338 — intervention group
Group type: EXPERIMENTAL
Intervention: SoftSeal
Number of subjects: 168
Study 15766338 — intervention group
Group type: COMPARATOR
Intervention: LMA Unique
Number of subjects: 168
Study 12942401 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg twice per day
Number of subjects: 265
Study 12942401 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg once per day
Number of subjects: 265
Study 12942401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 10789592 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha-2a, 6 MIU s.c. TIW for 4 weeks, followed by 3 MIU s.c. TIW, and 13-cis-retinoic acid 1 mg/kg/day p.o. BID daily
Number of subjects: 85
Study 10789592 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophosphamide 100-150 mg/day p.o. BID
Number of subjects: 85
Study 10789592 — intervention group
Group type: COMPARATOR
Intervention: No maintenance treatment (Control group)
Number of subjects: 85
Study 8863199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 17
Study 8863199 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 17
Study 8262820 — intervention group
Group type: EXPERIMENTAL
Intervention: BFM chemotherapy with 1800 cGy cranial irradiation
Number of subjects: 308